Interval to biochemical failure as a biomarker for cause‐specific and overall survival after dose‐escalated external beam radiation therapy for prostate cancer by Kapadia, Nirav S. et al.
Interval to Biochemical Failure as a
Biomarker for Cause-Specific and Overall
Survival After Dose-Escalated External Beam
Radiation Therapy for Prostate Cancer
Nirav S. Kapadia, MD1; Karin Olson, PhD1; Howard M. Sandler, MD2; Felix Y. Feng, MD1,3; and Daniel A. Hamstra, MD, PhD1
BACKGROUND: After external beam radiation therapy (EBRT) for prostate cancer, a short interval to biochemical fail-
ure of <18 months has been proposed as a surrogate for cause-specific survival. Because EBRT dose influences
biochemical failure, the authors investigated the interval to biochemical failure in a cohort of patients treated with
dose-escalated EBRT. METHODS: From 1998 to 2008, 710 patients were treated with EBRT (75 grays)  androgen
deprivation therapy (ADT) at the University of Michigan. Biochemical failure was defined using the Phoenix consensus
definition (nadir þ 2 ng/mL). A short interval to biochemical failure was defined as <18 months after completing
radiotherapy and/or ADT. The associations between biochemical failure, the interval to biochemical failure, and clinical
factors with cause-specific survival (CSS) and overall survival (OS) were evaluated. RESULTS: There were 149 bio-
chemical failures (21%), and short interval to biochemical failure accounted for 14% and 40% of biochemical failures in
those with intermediate-risk or high-risk disease, respectively. Biochemical failure impacted CSS (P < .0001) but not
OS (P ¼ .36). However, a short interval to biochemical failure predicted decreased CSS (P < .0001; hazard ratio [HR],
5.6; 95% confidence interval [CI], 2.4-13.0) and OS (P < .0001; HR, 4.8; 95% CI, 2.3-10.3) when compared with a long
interval to biochemical failure. The 8-year OS was 78% without biochemical failure, compared with 87% with a long
interval to biochemical failure (P ¼ .1; HR, 0.7; 95% CI, 0.4-1.1) and 38% with a short interval to biochemical failure (P <
.0001; HR, 3.7; 95% CI, 2.3-5.9). On multivariate analysis, a short interval to biochemical failure increased the risk of
prostate cancer death (P < .0001; HR, 18.1; 95% CI, 8.4-39) and all cause mortality (P ¼ .0027; HR, 1.5; 95% CI, 1.2-2.1),
whereas a long interval to biochemical failure did not. CONCLUSIONS: The relation between the interval to biochemi-
cal failure, CSS, and OS was independently validated in patients treated with dose-escalated EBRT. Further evaluation
of the interval to biochemical failure as a surrogate endpoint is warranted. Cancer 2012;118:2059-68. VC 2011 American
Cancer Society.
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INTRODUCTION
The long natural history of prostate cancer (PCa) has led to the search for biomarkers to be used as surrogates for either
cause-specific survival (CSS) or overall survival (OS). After prostatectomy, the presence of detectable prostate-specific
antigen (PSA) is defined as biochemical failure, whereas classifying biochemical failure after external beam radiation ther-
apy (EBRT) is more complex, because residual normal prostatic tissue remains, and the PSA remains detectable. The cur-
rent consensus (Phoenix) definition of biochemical failure after EBRT or brachytherapy with or without androgen
deprivation therapy (ADT) is when post-treatment PSA reaches at least 2 ng/mL greater than its lowest post-treatment (or
nadir) value.1 However, biochemical failure by itself does not necessarily portend a grave prognosis, a fact recognized both
by an American Society of Therapeutic Radiation Oncology consensus panel and the National Comprehensive Cancer
DOI: 10.1002/cncr.26498, Received: May 11, 2011; Revised: June 29, 2011; Accepted: July 18, 2011, Published online August 26, 2011 in Wiley Online Library
(wileyonlinelibrary.com)
Corresponding author: Daniel A. Hamstra, MD, PhD and Felix Y. Feng, MD, University of Michigan Health System, 1500 East Medical Center Drive, Floor B2,
Room C490, Ann Arbor, MI 48109-5010; Fax: (734) 763-7370; dhamm@med.umich.edu
1University of Michigan Medical Center, Ann Arbor, Michigan; 2Cedars Sinai Medical System, Los Angeles, California; 3Ann Arbor Veteran Affairs Medical System,
Ann Arbor, Michigan
F.Y.F. and D.A.H. contributed equally to this article.
Cancer April 15, 2012 2059
Original Article
Network (NCCN) guidelines.2,3 In fact, given the lack
of clearly proven benefit of early salvage ADT, these
bodies recommend that clinical failure—not biochemical
failure—indicates the need for salvage ADT.
Because of the poor specificity of biochemical fail-
ure for later clinical failure, several other metrics have
been evaluated as potential surrogates for clinical trial
design or by which to plan the use of salvage therapy.
The level and timing of PSA nadir have both been corre-
lated with biochemical failure, distant metastasis (DM),
and CSS in radiotherapy (RT) series4-9; both PSA veloc-
ity and/or doubling time10-12 have also been evaluated as
potential surrogates. However, each of these has been
demonstrated as an incomplete surrogate for CSS, with
even worse correlation with OS. The interval to bio-
chemical failure has also been evaluated as a surrogate for
DM and CSS in both surgical and RT series.13,14 Investi-
gators at Fox Chase Cancer Center evaluated the time
from the end of all therapy (EBRT and ADT) to bio-
chemical failure, and identified 18 months as a cutpoint
that was optimal as a potential surrogate for CSS.14 This
cutpoint was subsequently evaluated in a multi-institu-
tional series and found to be superior to both PSA nadir
and PSA doubling time as a surrogate for CSS.15 Analy-
sis of the TROG 96.01 randomized trial also established
an interval to biochemical failure of <24 months as a
potential surrogate for CSS among patients randomized
to low-dose (66 grays [Gy]) RT alone or with either 3 or
6 months of ADT.16 These studies all used either uni-
form low-dose RT16 or a broad range of RT doses,14,15
but because the level and timing of the PSA nadir as well
as biochemical failure are functions of RT dose, this
might influence the prognostic significance of the inter-
val to biochemical failure. Therefore, we sought to vali-
date the interval to biochemical failure in a cohort of
patients uniformly treated with dose-escalated RT.
MATERIALS AND METHODS
Patient Selection
Between 1998 and 2008, 718 PCa patients were treated
with dose-escalated EBRT  ADT at the University of
Michigan Medical Center (Ann Arbor, Mich). Informa-
tion about the interval to biochemical failure was available
for 99% (710 of 718) of patients, who form the cohort for
this analysis.
Informed Consent
This was a retrospective review that was institutional
review board-approved and not deemed to require
informed consent. However, from 2002 to the present, at
the time of radiation treatment patients have signed
informed consent to have their clinical information
included in the prostate database at the University of
MichiganMedical Center.
Staging
All patients were clinically staged per the American Joint
Committee on Cancer sixth edition staging criteria into
low-risk, intermediate-risk, and high-risk groups. Patients
with high-risk disease routinely underwent staging with
computed tomography (CT) and bone scan to rule out
metastatic disease. Per NCCN guidelines, staging was not
part of standard practice for those with low-risk or inter-
mediate-risk disease. In addition, neither endorectal coil
or pelvic magnetic resonance imaging were routinely
used. The Charlson Comorbidity Index was used to evalu-
ate comorbid illness and was evaluable in 97% (691 of
710) of patients.17
Treatment
Patients were treated based on CT planning with either 3-
dimensional conformal EBRT or intensity-modulated RT
prescribed such that the 95% isodose surface encompassed
the planning target volume (PTV). Low-risk patients were
treated at the prostate alone, and intermediate-risk patients
were routinely treated at the prostate and seminal vesicles.
High-risk patients routinely (87%) received treatment to
the pelvic lymph nodes followed by a boost to the prostate
and seminal vesicles. ADT was used in 39% of all patients:
11% (median, 4 months), 27% (median, 6 months), and
79% (median, 21 months) for low-risk, intermediate-risk,
and high-risk patients, respectively. For purposes of analy-
sis, short-term ADT was defined as <12 months, whereas
long-term ADT was defined as 12 months.
Follow-up and Endpoints
Follow-up and PSA were routinely obtained at 3- to 4-
month intervals for the first 2 years, every 6 months for 5
years, and every 6 to 12 months thereafter. The Phoenix
definition (nadirþ 2 ng/mL) was used to define biochem-
ical failure1; DMwas defined as any clinical, radiographic,
or pathologic evidence of DM. OS was defined as death
from any cause, whereas CSS was defined as 1) death
attributed to PCa or death in any patient with either 2)
castration-resistant PCa or 3) documented evidence of
metastatic disease before death. The time of follow-up
was based upon the last day of RT; however, the interval
to biochemical failure was defined based upon the time
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from the end of all therapy (RT or ADT) to biochemical
failure. Those who progressed while still on ADT were
scored as having an interval to biochemical failure of zero.
Statistical Analysis
Comparison between continuous variables was performed
with 1-way analysis of variance, whereas comparisons
between categorical variables used the chi-square test. The
log-rank test and Kaplan-Meier methods compared the
influence of single variables on survival endpoints,
whereas multivariate analyses were conducted using step-
wise Cox proportional hazard models.
RESULTS
Patient Characteristics and Follow-up
Median age at the time of treatment was 69 years (inter-
quartile range [IQR], 63-74), with no difference in age by
biochemical failure status (none, a short interval to bio-
chemical failure [<18 months from the end of all ther-
apy], or long interval to biochemical failure, Table 1).
Median follow-up was 64 months (IQR, 36-89): 57
months (IQR, 34-82) in those without biochemical fail-
ure, 69 months (IQR, 35-91) in those with a short interval
to biochemical failure, and 98 months (IQR, 71-131) in
those with long interval to biochemical failure. Not sur-
prisingly, patients with a short interval to biochemical fail-
ure were more likely to have higher-risk disease as
measured by PSA, TNM classification, Gleason score,
and risk group in comparison to those without biochemi-
cal failure or with a long interval to biochemical failure
(Table 1).
Biochemical Failure and Clinical Outcome
Biochemical failure was observed in 147 patients (21% of
all) at a median of 42 months (IQR, 22-67) from the end
Table 1. Clinical and Treatment-Related Factors
Variable No Biochemical Failure Biochemical Failure P
Short IBF Long IBF
Number of patients 563 41 106
Age, median y (IQR) 69.5 (63-74) 66.4 (59-75) 69.8 (64-73) .5a
CMI, mean 0.80 0.74 0.61 .066a
None 55% 64% 47% .03b
1 24% 18% 37%
‡2 21% 18% 16%
PSA (IQR) 7.8 (5.3-12.1) 26.1 (12.4-48) 11.3 (6.0-24) <.001a
Gleason score
2-6 39% 2% 25% <.0001b
7 45% 37% 51%
8 9% 22% 18%
9-10 7% 39% 6%
Clinical TNM classification <.001a
T1-T2a 77% 31% 57%
T2b-T2c 17% 20% 20%
T3-T4 6% 49% 23%
Radiation therapy
Dose, median Gy (IQR) 78 (76-78) 77 (77-78) 77 (76-78) .7a
Pelvic EBRT 23% 56% 39% <.0001b
ADT .004b
No 63% 39% 53%
Yes 37% 61% 47%
Duration, mo 6.8 (6.0-24.3) 24.9 (6.2-31) 6.4 (6.0-20.4) <.001a
NCCN risk group <.0001b
Low 26% 0% 12%
Intermediate 48% 17% 40%
High 26% 83% 48%
Abbreviations: ADT, androgen deprivation therapy; CMI, Charlson Comorbidity Index; EBRT, external beam radiation therapy; Gy, grays; IBF, interval to bio-
chemical failure; IQR, interquartile range; NCCN, National Comprehensive Cancer Network; PSA, prostate-specific antigen.
a Analysis of variance.
bChi-square.
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of EBRT. A short interval to biochemical failure was seen
in 41 patients, occurring a median 13 months (IQR, 8-
22) from the end of RT, whereas for those with a long
interval to biochemical failure this occurred a median 56
months (IQR, 40-80) after completing RT. Among the
160 low-risk patients, there were 13 biochemical failures
(8%) and no patients with a short interval to biochemical
failure. Among 319 patients with intermediate-risk dis-
ease, there were 49 biochemical failures (15%), and 7 of
these were with a short interval to biochemical failure (2%
of all intermediate-risk patients and 15% of all biochemi-
cal failures in this group). Among the 231 high-risk
patients, there were 85 biochemical failures (36%), and
34 of these had a short interval to biochemical failure
(15% of all high-risk patients and 40% of biochemical
failures in this group). The rates of PCa death (standard
error of the mean) were greater with increasing risk: 1%
(1%), 3% (1%), and 15% (5%) at 8 years for low-
risk, intermediate-risk, and high-risk patients, respectively
(P < .0001). No patient died of PCa without first experi-
encing biochemical failure. As a result, cause-specific sur-
vival was worse in those with biochemical failure for the
whole population (P< .0001) and when broken down by
NCCN risk groups (Fig. 1). However, the positive predic-
tive value of biochemical failure was low, as to date only
24% (36 of 147) of patients with biochemical failure have
died of PCa. In addition, there was no correlation
between biochemical failure and OS (P ¼ .38) even for
patients with high-risk disease (P¼ .8, Fig. 2).
Interval to Biochemical Failure and Clinical
Outcome
Because biochemical failure was poorly correlated with
CSS and OS, the impact of a short interval to biochemical
failure for subsequent clinical events was evaluated. At 8
years, patients with a long interval to biochemical failure
were less likely to experience metastasis, as compared with
those with a short interval to biochemical failure
Figure 1. Biochemical failure predicts for worse cause-specific survival among all patients (A), and as stratified by National Com-
prehensive Cancer Network risk group (low risk, B; intermediate risk, C; high risk, D).
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(metastasis-free rate, 79%  8% vs 33%  5%; P <
.0001; hazard ratio [HR], 4.2; 95% confidence interval
[CI], 2.2-8.0; Fig. 3A). Similarly, 7%  1% of patients
died of PCa at 8 years, and short interval to biochemical
failure predicted for worse CSS than long interval to bio-
chemical failure or no biochemical failure. No patients
without biochemical failure died of PCa; the 8-year free-
dom from PCa death was 87%  4% in patients with a
long interval to biochemical failure, and 44%  9% in
those with a short interval to biochemical failure (P <
.0001; HR, 5.6; 95% CI, 2.4-12.9; Fig. 3B). Finally, a
short interval to biochemical failure also predicted for
worse OS, with an 8-year rate of OS of 38%  9% in
those with a short interval to biochemical failure as com-
pared with 87% 4% in those with a long interval to bio-
chemical failure (P< .0001; HR, 4.9; 95% CI, 2.3-10.3).
Furthermore, OS among patients with a long interval to
biochemical failure did not differ significantly as com-
pared with those with no biochemical failure (P > .06;
HR, 0.7; 95%CI, 0.4-1.1; Fig. 3C).
Potential confounding factors that could limit the
applicability of the interval to biochemical failure were
next evaluated. The negative prognostic impact of a short
interval to biochemical failure on CSS and OS was evident
both in those treated with EBRT alone and those treated
with EBRT plus ADT. In those treated with EBRT and
no ADT, a short interval to biochemical failure carried an
8.8-fold increased risk for death from PCa as compared
with a long interval to biochemical failure (P < .0001;
95% CI, 2.2-36; Fig. 4A) and a 7.3-fold increased risk of
all cause mortality (P< .0001; 95% CI, 2.0-27; Fig. 4C).
For patients who received both EBRT and ADT, a short
interval to biochemical failure was associated with a 3.7-
fold increased risk of PCa death (P ¼ .003; 95% CI, 1.3-
10.7; Fig. 4B) and a 3.3-fold increased risk of all cause
mortality (P ¼ .0016; 95% CI, 1.3-8.1; Fig. 4D) as
Figure 2. Biochemical failure did not predict for worse overall survival among all patients (A), and as stratified by National Com-
prehensive Cancer Network risk group (low risk, B; intermediate risk, C; high risk, D).
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compared with a long interval to biochemical failure. As
above, patients with a long interval to biochemical failure
did not have significantly different OS as compared with
those without biochemical failure when treated with RT
alone (Fig. 4B) or when treated with RT þ ADT (Fig.
4D).
In addition, given the potential influence of age on
OS, the impact of a short interval to biochemical failure
was assessed as a function of age. When stratified by those
<60, 60 to 70, or >70 years of age, there was a similar
relation, such that in each age group a short interval to
biochemical failure predicted for worse OS, whereas a
long interval to biochemical failure did not (Table 2). We
also considered the possibility that a short interval to bio-
chemical failure resulted from less aggressive treatment,
especially as compared with patients with a long interval
to biochemical failure, and that this might explain a worse
clinical outcome. However, we found no difference in RT
dose based upon biochemical failure status (P ¼ .7, Table
1) and that pelvic EBRT fields were most commonly used
in patients who would later experience a short interval to
biochemical failure (P < .0001, Table 1). Patients with a
short interval to biochemical failure also received adjuvant
ADT more frequently than those patients with a long
interval to biochemical failure (61% vs 47%, P < .004)
and were treated with a longer duration of ADT (median,
25 vs 6 months; P < .001). Finally, patients with a short
interval to biochemical failure were not only more likely
to receive salvage ADT after biochemical failure, but also
as a group received it sooner than those with a long inter-
val to biochemical failure (P < .001; HR, 2.7; 95% CI,
1.6-4.5; Fig. 5). Two years after biochemical failure, 85%
 6% of those with a short interval to biochemical failure
received salvage ADT, whereas only 53%  6% of those
with a long interval to biochemical failure were accord-
ingly treated.
Figure 3. A short interval to biochemical failure (IBF) was associated with worse metastasis-free survival (A), cause-specific sur-
vival (B), and overall survival (C), as compared with long interval to biochemical failure or no biochemical failure.
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Multivariate Regression Results
Finally, a step-wise Cox proportional hazards regression
model was used to determine which factors were prognos-
tic for prostate-cancer specific death and overall mortality
(Table 3). Patients with Gleason scores >7 or a short
interval to biochemical failure were more likely to die of
PCa, whereas long-term ADT decreased the risk of PCa-
related death. Similarly multivariate analysis of OS
revealed that Gleason scores >7, advanced age, comorbid
illness, and a short interval to biochemical failure
increased the risk of all cause mortality. As above, long-
term ADT decreased the risk of all cause mortality.
Figure 4. The negative prognostic impact of a short interval to biochemical failure (IBF) on cause-specific survival (A, C) and
overall survival (B, D) was evident whether patients were treated with radiation therapy (RT) alone (A, B) or with androgen de-
privation therapy and RT (C, D).
Table 2. Short Interval to Biochemical Failure Predicts for Decreased Overall Survival Across All Ages
Group Overall Survival
All, N5718 Age <60 Years, n5121 Age 60-70 Years,
n5259
Age >70 Years, n5338
5 Years 8 Years 5 Years 8 Years 5 Years 8 Years 5 Years 8 Years
No BF 92% (91-93) 78% (75-81) 97% (95-99) 89% (83-95) 92% (90-94) 85% (81-89) 90% (88-92) 72% (67-77)
LIBF 95% (93-97) 87% (83-91) 92% (84-99) 92% (84-99) 97% (94-99) 95% (93-97) 92% (88-96) 79% (73-85)
SIBF 68% (60-76) 38% (29-47) 75% (62-78) 50% (33-67) 68% (60-76) 47% (33-61) 60% (46-74) 21% (8-34)
p <.0001 .0004 <.0001 <.0001
Abbreviations: BF, biochemical failure; LIBF, long interval to biochemical failure; SIBF, short interval to biochemical failure.
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Factors that were evaluated, but not prognostic for either
CSS or OS, included PSA (as a continuous variable),
Gleason score 7, clinical TNM classification, the use of
short-term ADT, pelvic RT, and biochemical failure>18
months from the end of treatment.
DISCUSSION
Given the long natural history of PCa, several biomarkers
that may act as surrogates for CSS and OS have been eval-
uated.10,14,16 In the present study, we independently vali-
dated the interval to biochemical failure as a surrogate for
metastasis-free survival and CSS in patients treated with
dose-escalated EBRT (with or without ADT), using a pre-
viously determined cutpoint of 18 months. Multivariate
analysis confirmed that a short interval to biochemical
failure was the strongest prognostic factor for CSS, associ-
ated with an 18-fold increase in the risk of PCa death.
More importantly, multivariate analysis demonstrated
that patients with a short interval to biochemical failure
were 1.5 more likely to die from any cause than those
without biochemical failure. This was clearly influenced
by the finding that 77% of the patients treated in this
cohort had intermediate-risk or high-risk disease. Interest-
ingly, those with a long interval to biochemical failure did
not have worse OS when compared with those without
biochemical failure, which was confirmed uponmultivari-
ate analysis. Not surprisingly, given that most deaths in
the group were not because of PCa, patient age and the
presence of comorbid illness more significantly impacted
OS than did the interval to biochemical failure. From this
retrospective review, were are unable to make comment as
to the impact of metastatic failure versus local failure;
however, given the benefit observed through the addition
of RT to ADT and vice versa, it is clear that both local and
systemic control are likely of importance.
The benefit of ADT in concert with EBRT has been
demonstrated in multiple randomized trials, as shown by
improved disease-specific (and in some studies, overall)
survival in patients with locally advanced and/or high-
grade PCa treated with conventional dose RT.18-20 How-
ever, the timing of ADT after biochemical failure is more
controversial. The NCCN has suggested deferring salvage
hormonal therapy until documented metastatic or symp-
tomatic disease.2 Other authors, however, advocate early
Figure 5. Patients with a short interval to biochemical failure
were more likely to receive salvage androgen deprivation
therapy (ADT) and received ADT earlier than those with late
failures. CI, confidence interval; HR, hazard ratio.
Table 3. Multivariate Cox-Proportional Hazards Analysis of Cause-Specific and Overall Survival
Covariate Cause-Specific Survival Overall Survival
p HR 95% CI p HR 95% CI
Gleason score 2-6 Reference Reference
Gleason score 8 <.04 2.5 1.1-5.4 .0010 2.4 1.4-4.2
Gleason score 9-10 <.0001 12.3 5.6-28 <.0001 17.9 9.6-33
No ADT Reference Reference
LTAD therapy .0013 0.20 0.07-0.52 <.0001 0.20 0.08-0.36
No BF Reference Reference
Short IBF <.0001 18.1 8.4-39 .0027 1.5 1.2-2.1
Agea <.0001 1.09 1.06-1.11
CMIb <.0001 1.4 1.2-1.6
Abbreviations: ADT, androgen deprivation therapy; BF, biochemical failure; CI, confidence interval; CMI, Charlson Comorbidity Index; HR, hazard ratio; IBF,
interval to biochemical failure; LTAD, long-term androgen deprivation.
Variables evaluated but that were not prognostic included: prostate-specific antigen, TNM classification, Gleason 7, short-term ADT, the use of pelvic radio-
therapy, and BF (with a long IBF).
a Age as a continuous variable per year.
b CMI as a continuous variable per point.
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ADT use to prevent the morbidity of potentially sympto-
matic metastatic disease.21 Although randomized investi-
gations have failed to show a survival benefit in upfront
versus delayed use, there does appear to be a benefit to im-
mediate (and indefinite) ADT use in at least the postoper-
ative setting for lymph node-positive patients.22
A secondary analysis of RTOG 85-31 (which
randomized patients with locally advanced PCa to EBRT
alone vs EBRT with lifelong adjuvant ADT) evaluated
patients allocated to the RT-alone arm and divided them
into 2 groups: early salvage therapy versus late salvage
therapy as defined by the PSA level at which salvage was
initiated, using 10 ng/mL as a threshold. Multivariate
analysis demonstrated a statistically significant improve-
ment in OS among patients who were salvaged before
their PSA level reached 10 ng/mL, although interestingly
no significant differences were observed in either CSS or
local control.23 This suggests a possible bias toward using
salvage ADT in those who were overall in better health. A
similar secondary analysis was conducted for the RTOG
86-10 trial (which randomized patients with locally
advanced PCa to EBRT alone vs EBRT þ 4 months neo-
adjuvant and concurrent ADT). For patients randomized
to RT alone (without adjuvant ADT), the initiation of sal-
vage ADT before metastasis improved both OS and
CSS.24 The results of the present analysis would seem to
reinforce the above findings, suggesting that patients with
a short interval to biochemical failure harbor aggressive
disease and may stand to benefit from early and aggressive
salvage therapy.
The primary strengths of this study include the con-
temporary and consistent treatment of patients over a 10-
year period. These patients were treated in the modern era
of dose-escalated EBRT, and as such the minimum PTV
treatment dose was 75 Gy. This is in contrast to the report
by Buyyounouski and colleagues, where the median radio-
therapy dose was 72 Gy and the minimum reported dose
was 67 Gy,14 and the TROG 96.01 study, where the pre-
scribed RT dose was 66.6 Gy.16 The dose of RT is rele-
vant because increased dose is more likely to improve local
and biochemical control and has been demonstrated to al-
ter the timing of PSA response, which could potentially
impact the relevance of a short interval to biochemical
failure.25 Limitations in the current data include the retro-
spective analysis and the relatively few events. In addition,
the duration of ADT can influence the timing of testoster-
one recovery,26 which in turn may delay the rise of PSA,27
thereby altering the prognostic significance of the interval
to biochemical failure. Unfortunately, we were unable to
control for testosterone recovery in the current analysis, as
these data were not routinely obtained.
Conclusions
A short interval to biochemical failure, defined as within
18 months of completing therapy (EBRT and/or ADT),
correlated with a significantly increased rate of distant me-
tastasis, decreased CSS, and decreased OS, as compared
with a long interval to biochemical failure or a lack of bio-
chemical failure. We are encouraged that this easily deter-
mined PSA-derived endpoint predicts for OS after RT in
PCa. Nevertheless, these data regarding the interval to
biochemical failure are hypothesis generating and must be
validated within other datasets or randomized trials before
gaining widespread acceptance.
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